A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck

NCT03620123 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Carcinoma, Squamous Cell of Head and Neck

Interventions

DRUG: Nivolumab and Ipilimumab
DRUG: Docetaxel

Sponsor

AIO-Studien-gGmbH

Collaborators

[object Object]